Search research articles
Contact Us
Filters
Showing results (181-190 of 323) with videos related to
Page
of 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Tin-Yun Tang, Federico Nichetti, Ben Kaplan, et al.
Plos One
|
January 17, 2023
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses
Alberto D'Angelo, Huseyin Kilili, Robert Chapman, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
The Oncologist
|
October 9, 2015
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, et al.
Clinical Colorectal Cancer
|
September 1, 2023
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
Filippo Ghelardi, Alessandra Raimondi, Federica Morano, et al.
British Journal of Cancer
|
August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Alexej Ballhausen, Federica Morano, Arndt Stahler, et al.
The Oncologist
|
May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program
Chiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
JAMA Oncology
|
November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
Oncology
|
May 4, 2019
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
Rosalba Miceli, Jiyeong An, Maria Di Bartolomeo, et al.
Page
of 33
Search research articles
Search
Showing results (181-190 of 323) with videos related to
Sort By:
Page
of 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Tin-Yun Tang, Federico Nichetti, Ben Kaplan, et al.
Plos One
|
January 17, 2023
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses
Alberto D'Angelo, Huseyin Kilili, Robert Chapman, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
The Oncologist
|
October 9, 2015
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, et al.
Clinical Colorectal Cancer
|
September 1, 2023
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
Filippo Ghelardi, Alessandra Raimondi, Federica Morano, et al.
British Journal of Cancer
|
August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Alexej Ballhausen, Federica Morano, Arndt Stahler, et al.
The Oncologist
|
May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program
Chiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
JAMA Oncology
|
November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
Oncology
|
May 4, 2019
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
Rosalba Miceli, Jiyeong An, Maria Di Bartolomeo, et al.
Page
of 33